We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration.
- Authors
Walther, Feli M.; Paul, Allan J.; Allan, Mark J.; Roepke, Rainer K. A.; Nuernberger, Martin C.
- Abstract
Background Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tickcontrol after a single oral dose. This study investigated the safety of oral administration of fluralaner at 3 times the highest expected clinical dose to Multi Drug Resistance Protein 1 (MDR1(-/-)) gene defect Collies. Methods Sixteen Collies homozygous for the MDR1 deletion mutation were included in the study. Eight Collies received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed Collies served as controls. All Collies were clinically observed until 28 days following treatment. Results No adverse events were observed subsequent to fluralaner treatment of MDR1(-/-) Collies at three times the highest expected clinical dose. Conclusions Fluralaner chewable tablets are well tolerated in MDR1(-/-) Collies following oral administration.
- Subjects
DRUG administration; ANTIPARASITIC agents; FLEA control; DRUG resistance in microorganisms; COLLIE
- Publication
Parasites & Vectors, 2014, Vol 7, Issue 1, p1
- ISSN
1756-3305
- Publication type
Article
- DOI
10.1186/1756-3305-7-86